October 15-18, 2026
Global Site Solutions Summit™

Key Takeaways

This collection brings together session briefs from the 2026 SCRS Global Site Solutions Summit, authored by the site leaders, CRO partners, sponsors, and SCRS team members who were in the room.

Toggle Custom CSS

AI Basics: Real-World Site Application

Michelle Hartmann | South Broward Research

This session looked at how research sites of different sizes are putting AI to work today, from prescreening and source building to inventory management and query reduction. It matters because AI is quickly becoming part of daily site operations, and sites that implement it safely and deliberately are already seeing better data quality and fewer errors.

What sites can do:

  • Write AI SOPs before rolling out any tool, and confirm the platform is a closed, non-learning system.
  • Train staff to use AI safely so confidentiality agreements are not compromised.
  • Designate an AI super user, and consider including AI experience in hiring.
  • Ask your team how they feel about AI, and listen to their concerns.
  • When evaluating a platform, ask how many users are included and how the pricing works.
  • Add technology fees to study budgets, both initial and annual, covering AI systems as well as eSource and eReg.
  • Prepare a justification document that lists the AI tools your site uses and explains that they run in a closed, non-learning system. Use it when negotiating CTAs that restrict AI.
  • Reach out to other sites that have already implemented AI to learn from their experience.
  • Start with practical uses such as prescreening and enrollment through review of EMRs and databases, budgeting, source building, and supply tracking.

Looking ahead, how sponsors handle AI in CTAs is still unsettled. Some prohibit it, while many use AI in their own work through closed systems for their employees. Clear communication between sites, sponsors, and CROs about what is allowed will be important, and trust and partnership were recurring themes as the industry works this out.

The panel and audience also encouraged sites to stay curious, since experimenting helps you find uses beyond your first ideas. The tools discussed came from vendors and were also built in house, so sites don’t need to wait for a perfect commercial product to start.

Key Takeaways

  1. AI won’t replace coordinators, but coordinators who don’t know AI are replaceable. The more a team uses AI, the more helpful it becomes, so building staff skills now pays off.
  2. Safe implementation starts at the top. Leadership has to drive it, SOPs need to be in place first, and tools must run in a closed portal that does not use site information to train its learning models.
  3. Some sponsors are adding CTA clauses that prohibit AI use during any part of a trial. The panel and several audience members recommended not accepting these restrictions outright and negotiating instead.
  4. Sites are seeing measurable results. One site reduced queries with a tool that compares all of its systems and builds source more efficiently. Another reduced protocol deviations and missed assessments through better source, which also built coordinator confidence. A third improved quality by integrating systems to follow the full participant journey and by tracking supplies and lab kits with an inventory management system.

Resources mentioned:

Ask, Don’t Assume: Cut25 In Action

Naila Aslam | Revival Research

This session focused on reducing unnecessary training at the site through close collaboration between sites, CROs, and sponsors. The goal is to ensure sites receive quality training that centers on the protocol rather than on systems.

Sites can work closely with CROs, vendors, and sponsors to help draft protocol-specific training on the platform, rather than accepting general system training. They can also request system training alongside protocol training for new site staff.

Key Takeaways

  1. Offer more protocol training than system training.
  2. Conduct competency assessments before offering training sessions.
  3. Focus on quality training sessions.
  4. Eliminate unnecessary training.

 

Benchmarking The KPIs That Matter

Karri Venn | ClinSurge

Public benchmarks give a site something to measure itself against. They work best as a direction, not a contract term, because results shift with therapeutic area, phase, sponsor and site type.

Module 1: Site Start-Up

Measure the clock from site selected to first patient enrolled and keep greenlight to first patient as a second marker. Three targets for the site:

  • Turnaround: return regulatory documents and contracts/budget responses within 24 hours from your site.
  • First patient: enroll within 5 days of greenlight.
  • Escalation: if a budget or contract goes unanswered for one week, escalate, and keep escalating until you have a response to your proposals.

For context, public data put budget finalization at about 52.5 days and the full contract cycle at about 63.8 days.

Module 2: Enrollment and pace

Paced ratio shows whether a study is on track for the goal agreed with the sponsor. One simple way to calculate it is actual randomizations to date divided by the randomizations expected to date at the agreed pace. A reading of 1.0 is on pace. For example, a goal of 12 over 6 months expects 6 by month three. With 5 randomized, the ratio is 0.83.

Set green, yellow, and red bands before the study opens, so action is not a judgment call. Illustrative bands are green at 0.90 or above, yellow from 0.70 to 0.89, and red below 0.70. Yellow prompts a review of strategy, such as database re-contact or added outreach. Red prompts a recovery plan and an early conversation with the sponsor. Definitions of pace vary between sites, so confirm yours with your team.

Screen fail rates depend on therapeutic area. Public averages run 36.3% overall, 57% in CNS and neurology, and 20% to 30% in oncology. Track your own ratio by area, ask for study status updates, and compare with how all other sites are performing. To plan screens, divide randomizations needed by one minus the screen fail rate. Twelve randomizations at a 40% screen fail rate need about 20 screens.

Module 3: Quality and rework

Sponsors are putting more weight on query resolution, query aging, time to data entry, physician sign-off, and protocol deviations. Medidata reports query aging as the share of queries open past 48 hours, 30 days, and 75 days, and time to data entry as the days from clinic visit to EDC submission.

Ask your EDC vendor and sponsor how you perform and which metrics they watch, ideally with a comparison to other sites. Track minor and major deviations separately. Public data show major deviations touch about 9.2% of randomized patients, far fewer than the all-deviations figure.

Module 4: People and capacity

Enrollment goals and quality both depend on whether the team has room to do the work. Public data put the median CRC load at 7 studies a year and about 80 patients a year. Your own ceiling will differ by phase and indication, so work out how many active studies, active participants, and weekly visits one CRC can carry before quality slips and say whether you count FTE or headcount.

Watch for early signs of overload: late data entry, more deviations, a growing query backlog, and turnover. Public figures put annual staff turnover at 35% to 61%, roughly double the pre-pandemic range. A common way to calculate it is the people who left in 12 months divided by average headcount. Also measure ramp-up, meaning the months until a new CRC runs a full caseload alone, along with the cost in recruiting, training, and missed enrollment. Consider ways to reduce overall turnover as your weight in study performance is based on the incredible value of your CRCs.  Find ways to best support CRCs workload ie. Recruitment, Data Management, Lab Support all improves job satisfaction and general performance.

Module 5: Financial health

Understand the financial numbers of operating your business and decide who else sees them. Good assessments include revenue per CRC, EBITDA margin, aging receivables, and cash flow. An EBITDA margin of 25% to 50% signals strong operational discipline, and 30% is a sound goal for a healthy site.

For revenue and expense per FTE, state which staff you count and which revenue you use. Collected revenue and clinical FTE are the easiest to compare across sites. Decide in advance what expense per FTE would make you worry.

Review receivables by bucket: 0 to 30, 31 to 60, 61 to 90, and over 90 days. Public averages run 118 to 140 days, and 23% of sites report that 31% to 40% of their invoices are overdue by 90 days or more. Know which sponsors or CROs sit in the oldest bucket, what causes it, and what you do at 60 and at 90 days. Also check revenue concentration. If your top two sponsors or CROs supply most of your revenue, that is a risk, and it can weaken your hand in negotiation. About half of sites hold less than three months of operating capital, so cash runway deserves a regular look.

Co-Creation Lab: Recruitment Strategies

Karri Venn | ClinSurge

Sites and sponsors agree that recruitment costs real money. They often disagree on where it should go. Two pieces of work from SCRS Global point in the same direction. The payment stream guide, Recruitment Initiatives in Clinical Research (SCRS, 2025), lists what sites spend on recruitment. The co-creation lab shows what sites say they use and need.

What the guide covers

Sites report $5k to $25k or more in recruitment-related costs per study. The guide sorts those costs into five areas.

  • Practice-based recruitment: EMR queries and chart review, often billed per chart or as a fixed fee. Third-party screening tools may be needed, with costs passed through.
  • Media outreach: IRB/REB-approved materials, radio, print, TV, social media, and central campaign management. Every channel needs people and systems to handle the leads it produces.
  • Physician outreach: referral materials, lunch-and-learns, and office visits, all of which take compensated time.
  • Community engagement: events, outreach staff time, travel, pharmacy and lab partnerships, and patient advocacy groups.
  • General recruitment support: pre-screening, point-of-care tests, technology setup, translation, printing, direct mail, and staff time, usually negotiated as hours multiplied by an hourly rate.

The guide also says contracts should reimburse pre-paid recruitment costs if a study is cancelled. It asks sites to track what their efforts produce and report it back, since results make the next funding request easier.

What the co-creation lab added

The lab covered similar ground from the site side. Participants listed strategies of preference such as targeted outreach, central campaigns run by a site network or a vendor, advertising, word of mouth, email and text outreach, patient support groups, and data mining of clinic, pharmacy, and research database records. They also named physician outreach, pre-screening with a generic consent form for research-ready candidates, and point-of-care tests or added labs to clinic requisitions.  Interestingly, of the sites present the most valued was use of data mining tools to identify and support outreach to study candidates.

They listed the people involved and the specific skillsets required for success: recruiters, screening coordinators, navigators, marketing support, and was impressed to see more external help from the sponsor or CRO to supplement the lack of resources at a site during enrollment peak. Finally, consideration of the type of technology to deploy: AI vendors, a CRM for text, email, and API connections, VOIP call centers, chatbots or agentic AI support, and electronic consent platforms.

The main message was about choice. Most sites do not want a full package of resources handed to them. They said much of what is offered goes unused, does not reflect the communities they serve, or is not the approach that works best for their site.

What this means for budgets

The guide gives sponsors and CROs a menu of fundable items. The lab says sites want to pick from that menu, not receive a standard or fixed choice.

Together they support three requests.

  1. Offer recruitment funding as a flexible budget a site can allocate, not a preset set of services. As well, avoid any waste or funds deployed in areas that will not be used.
  2. Cover the people and systems behind each channel, not only the advertising itself.
  3. Agree up front on cancellation reimbursement and on how results will be reported to continue to receive support for positive results.

A site that knows what works for its patients, and has the funding to act on it, should enroll faster and more representatively than one working from a standard kit or underfunded both in dollars and/or people.

From Feasibility To First Choice: What Sponsors Really Want

Karen Kolin | Novo Nordisk

This session focused on how sponsors and CROs build site lists, and how sites can show they are a credible, well-matched choice, not just a site with a high patient number. Sponsors combine protocol needs, patient access, timelines, budget, and available performance data to build targeted lists. Beyond enrollment projections and therapeutic experience, they want confidence in a site’s communication, operational readiness, and ability to deliver.

What sites can do:

Make your site discoverable

  • Get your site and investigators into sponsor and CRO databases, and keep your profiles current. Complete profiles help teams match site capabilities to studies. Accurate external database records and a detailed site website can also improve discoverability.
  • Network at industry events to find the right contact.
  • If your investigator receives feasibility requests directly, set up a shared site email monitored by more than one person. Surveys may go to the PI, and requests sent directly to PIs can get lost in their inboxes. Sponsors and CROs often use automated systems to distribute opportunities, so a dedicated, centralized feasibility address helps ensure requests are received and answered within a short response window.

Make feasibility responses specific and realistic

  • Use free-text fields to describe relevant experience, referral pathways, patient access, and what supports your estimate. Be candid, because panelists said they compare responses with historical data and may verify outlier estimates.
  • If a question about patients “treated” doesn’t fit your model, such as at a dedicated research site, explain how you access the population (for example, through referrals or community providers). Give a reasonable estimate of screenable and enrollable patients instead of a misleading zero with no context.
  • Complete every field and follow the survey instructions. Feasibility windows can be short, and surveys may close once enough responses arrive.
  • Ask sponsors directly about minimum enrollment expectations, and review comparable studies on ClinicalTrials.gov to build realistic projections.
  • The discussion also covered tailoring feasibility questionnaires to site type and capabilities to improve efficiency.

Build a reliable path from survey to selection

  • Keep contact details current for the PI and the person who handles feasibility. If the PI is unavailable or no longer at the site, use the contact provided with the survey to clarify the right replacement.
  • CRO timelines are often driven by the sponsor, which can limit the CRO’s flexibility to give updates or speed up decisions. Ask early about anticipated selection timelines to help manage expectations.
  • Treat pre-award feasibility as visibility, not a firm commitment. Responding sites may be included in information shared with the sponsor, but the final list depends on study needs and further validation.

Standardize and leverage what you have

  • Submission expectations vary by sponsor, and there is no universal approach. Keeping site and PI capability information consistent and standardized helps streamline submissions across different feasibility portals.
  • Sponsors may consider case studies from other therapeutic areas. Demonstrated success in enrollment, retention, startup, and operational execution can build confidence, even without direct experience in a particular indication.

Key Takeaways

  1. Show a credible match, not just a patient number. Sponsors weigh protocol needs, patient access, timelines, budget, and performance data, along with your communication and operational readiness.
  2. Make it easy for sponsors to find you. Keep database profiles current and use a shared feasibility email so requests are not missed.
  3. Be specific and realistic in feasibility responses. Explain how you reach patients, support your estimates, and expect them to be checked against historical data.
  4. Respond completely and on time. Windows are short, and surveys may close once enough responses arrive.
  5. Treat feasibility as visibility, not a commitment. Ask about selection timelines early and keep your contact details current.
  6. Use your whole track record. Standardize your site information, and use results from other therapeutic areas to build confidence.

Future-Proofing Your Site: Forecasting & Resilience

Bailey Jordan | Worldwide Clinical Trials

Clinical research sites operate in an environment of constant change, from shifting sponsor pipelines and enrollment expectations to evolving technology, workforce demands, and study complexity. This session explored how sites can move beyond reacting to immediate challenges and build the visibility, flexibility, and relationships needed to prepare for what comes next.

Future-proofing does not mean predicting every change or getting every forecast exactly right. It means having enough visibility into your pipeline, operations, and finances to recognize change early and respond thoughtfully. Strong forecasting is iterative: forecast, measure, compare against actuals, learn, and adjust. Over time, this helps sites and networks understand what is realistic for their organization and make better decisions about staffing, investment, study selection, and growth. Resilience comes from being prepared to adjust, and sites that understand both where their business is headed and where it stands today will be better positioned to handle uncertainty and still grow sustainably.

What sites can do:

  • Track pipeline visibility alongside staffing, facility, and operational capacity.
  • Use historical performance to set realistic enrollment and resource assumptions.
  • Maintain proactive relationships with sponsors, CROs, and industry partners between opportunities.
  • Evaluate studies on strategic and operational fit, not availability alone.
  • Develop contingency plans for delayed starts, shifting timelines, enrollment challenges, and staffing changes.
  • Clearly communicate what differentiates your site and where it can deliver the greatest value.

Key Takeaways

  1. Understand the difference between accrual and cash flow. Revenue earned or work performed does not mean cash has been received. Sites and networks need visibility into both expected revenue and the timing of actual payments to make responsible decisions on staffing, investment, and growth.
  2. Forecast, then continuously reconcile against actuals. A forecast is a living tool, not a one-time projection. Comparing expected study starts, enrollment, revenue, expenses, and payment timing against what actually happens shows where assumptions are consistently too aggressive or too conservative, and makes future forecasts more realistic.
  3. Plan for timing variability. Start-up delays, slower-than-expected enrollment, milestone-based payments, and invoicing cycles can create a gap between projected revenue and available cash. Build financial plans with this in mind so commitments are not based solely on projected activity.
  4. Accept that forecasting will never be perfect. The goal is not perfect prediction. Forecasting is an iterative process of setting assumptions, monitoring performance, understanding variances, and adjusting the model.
  5. Find the model that works for your site or network. No single methodology fits every organization. A single site, a multisite network, and a larger organization may need different levels of detail and different forecasting horizons. What matters is a repeatable process that gives leadership enough visibility to make informed decisions.

Global Advantage: International Site Positioning

Guillermo Ortiz | Fundacion Estudios Clinicos

This session explored how international sites can influence country selection by demonstrating patient access, therapeutic expertise, and predictable execution. Drawing on experiences from Latin America, Canada, Australia, and New Zealand, the discussion highlighted practical ways to challenge outdated perceptions, build partnerships, and engage sponsors and CROs before feasibility decisions are made.

What sites can do:

  • Prepare a one-page capability profile focused on your strongest therapeutic areas. Include documented patient access, recruitment and retention performance, investigator experience, and actual startup timelines. Distinguish your site’s results from national averages when those averages don’t represent your operating model.
  • Map the activation pathway from study selection to first participant enrolled. Assign responsibility for each milestone, identify activities that can run in parallel, and communicate realistic timelines. Faster regulatory review will have limited impact if budget negotiations or staff preparation remain unresolved.
  • Build relationships with sponsor feasibility teams and CRO country leaders before questionnaires arrive. Use those conversations to understand protocol needs, explain local standards of care, and address concerns about logistics or country requirements.
  • Identify complementary sites and develop a joint proposal for a defined study need. Specify which locations offer the relevant patients, how communication will work, and how the group will coordinate delivery.
  • After each study, compare commitments with results and use that evidence to strengthen future proposals.

Looking ahead, the discussion raised the question of how country selection can better reflect current capabilities and changing patient populations rather than historical study footprints. Participants saw opportunities for more forward-looking use of data and AI, greater regulatory and ethics harmonization, and stronger national collaboration. Sites should watch whether regulatory improvements lead to shorter overall activation timelines, and whether emerging sponsor priorities match their therapeutic strengths.

The audience discussion extended these challenges to less represented research markets, including Nigeria. The practical message: identify a specific strength, connect it to an unmet study need, and deliver reliably when the first opportunity comes. Country-level visibility and individual site performance reinforce each other, so collaboration is valuable even among sites that compete for studies.

If Only You Knew: Building Stronger Partnerships

Susan Baumohl | AMR Clinical

Every stakeholder in clinical research operates under constraints that the others rarely see or understand. This session asked how sponsors, CROs, and sites can align their expectations, timelines, deliverables, and processes so their partnerships are built on transparency, flexibility, and trust.

A better partnership does not mean everyone shares the same priorities. It means all parties understand the realities and issues behind each other’s decisions and actions, and trust one another enough to discuss them before they become overwhelming problems. Each stakeholder’s actions affect the others.

What stakeholders can do:

  • Work together to change course when something isn’t working.
  • Start difficult conversations without blame or animosity.
  • Remember that collecting data can take time.
  • Know which of your company’s constraints are non-negotiable.
  • Stop following outdated processes simply because they have always been done that way.

Key Takeaways

  1. Delivering what you promised is critical.
  2. Not every Phase II trial that completes has a Phase III immediately following it.
  3. A PI with little to no experience in a specific indication can successfully enroll and complete a trial.
  4. Sites with previous compliance issues or CAPA/mitigation plans should lead with that information during site selection.
  5. What can appear to be unwillingness or inflexibility is often outside the stakeholder’s control.

Leading With Culture: Building Strong Teams

Wes Bonner | DM Clinical Research

This panel explored how leadership teams can successfully integrate clinical research organizations while balancing organizational consistency with local team culture and autonomy. One panelist emphasized a top-down approach to culture, where leadership sets clear expectations, communicates core principles, and demonstrates the behaviors it wants the organization to adopt. The panel also discussed the challenges of acquisitions and integration. The central theme was that culture is a strategy built on principles, not simply a set of values written on a wall.

The key recommendation was to establish a culture and integration framework for bringing new practices, investigators, and research sites into the organization. Review these categories with the local leadership team during onboarding, and revisit them every 30 days until you reach 90 days. This supports the transition and integration and allows the company culture to evolve.

Looking ahead, the panel raised these questions:

  • How do you scale a consistent culture without creating a one-size-fits-all operating model? This is especially relevant as research networks expand through acquisitions, embedded sites, and partnerships with independent physician practices.
  • How can leadership measure cultural alignment beyond employee satisfaction surveys?
  • What is the right balance between centralized leadership and decentralized decision-making while integrating a culture strategy?

The ultimate goal is not to make every site operate identically to every other site. It is to ensure that every site operates according to the same cultural principles while preserving the strengths that make it successful. The most successful organizations set clear cultural expectations, model them consistently, and give local teams enough autonomy to succeed.

Key Takeaways

  1. Culture starts at the top. Create core values and demonstrate them through visible leadership actions.
  2. Standardization must be balanced with local autonomy. Leave room for flexibility in local workflows, team dynamics, and practices that support employee engagement and site-level effectiveness.
  3. Trust is built through visible leadership and recognition. Work alongside teams rather than just giving directives, recognize positive behaviors with call-outs and shout-outs, and keep communication open.
  4. A rising tide raises all boats. When one person or team succeeds and grows, others benefit too. This applies especially to building a great team and leading with culture.

 

What You’re Not Charging For: From Identification to Justification

Michele Cameron | Clearwater Cardiovascular Consultants

This breakout focused on the costs a site can incur beyond what appears in the Sponsor/CRO budget template. Most clinical trial budgets are built mainly on the Schedule of Assessments, but sites must consider many other costs. Examples include training and re-training, patient comfort (a dedicated waiting area, food, travel, companions), politically driven expenses such as import delays, overhead variations, extra staff or subcontractors for specialized procedures, and technology fees for time spent troubleshooting.

The panel emphasized that every site is unique and must take responsibility for knowing its true financial needs and justifying what it asks for. Sites that know their numbers can negotiate to make a profit, so they are available for the next study, and can be prepared to walk away.

Attendees said they sometimes felt compelled to accept low-budget studies. The reasons included a PI insisting on the study for scientific or publishing purposes, and the need for some cash flow to keep the doors open while waiting for a more lucrative study. The panel pointed to the downsides:

  • Sponsors and CROs keep historical budgets and often base the next budget on them.
  • A low budget can lower the negotiation bar for other sites.
  • Future study awards can suffer if the site struggles to enroll and meet goals on a low-budget study.

The panel also advised asking what is included in catch-all line items such as Start Up, Close Out, and Administrative Fees, since every sponsor and CRO includes different services under these headings. Sites should add any items that are not covered.

CRO panelists explained that budgets reflect several factors: FMV tables, geographic area, population hot spots, site type, and sponsor preferences. The negotiator works within ranges set between the sponsor and CRO. If a site is not getting the fee it requests, it can ask for escalation, but should first consider whether the difference is significant enough to justify extending the timeline and delaying first-subject enrollment.

Fun fact: CROs and sponsors may use AI when negotiating budgets, yet many sponsors contractually prohibit sites from using AI. Sites should review these clauses closely.

Key Takeaways

  1. Evaluate and know the costs you will incur with each study before negotiations begin, and be ready to walk away.
  2. Prepare justifications for your budget line items. Some suggested sharing them at the start of negotiations to save time.
  3. Clarify what is actually included in the Sponsor/CRO budget template.
  4. Visit the Site Invoiceables Toolkit on the SCRS website for more suggestions.